999 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
PFE Pfizer, Inc. $43.01 $252.13B N/A
Article Searches
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Kidney-Cancer Market: Good for Patients, Hard for Investors https://www.fool.com/investing/2019/04/23/kidney-cancer-market-good-for-patients-hard-for-in.aspx?source=iedfolrf0000001 Apr 23, 2019 - Drugmakers battle for patients.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release http://www.zacks.com/stock/news/391530/pfizer-pfe-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release?cid=CS-ZC-FT-391530 Apr 23, 2019 - Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Bayer (BAYRY) This Earnings Season? http://www.zacks.com/stock/news/390421/whats-in-store-for-bayer-bayry-this-earnings-season?cid=CS-ZC-FT-390421 Apr 22, 2019 - Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? http://www.zacks.com/stock/news/390180/exact-sciences-exas-to-post-q1-earnings-whats-in-store?cid=CS-ZC-FT-390180 Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Wave Life Sciences Plunges After DMD Study Data Readout http://www.zacks.com/stock/news/386326/wave-life-sciences-plunges-after-dmd-study-data-readout?cid=CS-ZC-FT-386326 Apr 17, 2019 - Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
These 3 Value Stocks Are Absurdly Cheap Right Now https://www.fool.com/investing/2019/04/09/these-3-value-stocks-are-absurdly-cheap-right-now.aspx?source=iedfolrf0000001 Apr 09, 2019 - Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.

Pages: 1234567891011...100

<<<Page 6>